Health Care/Hospital
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024
NANJING, China, May 21, 2024 /PRNewswire/ -- The 10th European Stroke Organization Congress (ESOC), held inBasel, Switzerland from May 15 to 17, 2024 , showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) and a new dosage form of sublingual tablets unde...
2024-05-21 15:52
1304
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
YONGIN, South Korea, May 21, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A. With this FDA clearance,...
2024-05-21 15:12
1420
Dr. Philip Fan J.P. (范榮彰博士) Opens One-Stop Dental Facility in Shenzhen to Cater to New Consumption Patterns of Hong Kong Residents
HONG KONG, May 21, 2024 /PRNewswire/ -- The lifting of pandemic travel restrictions has driven a surge of Hong Kongers visiting mainlandChina for consumption, with dental services becoming a popular spending category. The dental clinic opened inShenzhen by Dr. Philip Fan, J.P. (范榮彰博士), the former...
2024-05-21 14:37
16611
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
* Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2] * Data from a post-hoc analysis of the LIBERTY-CD study showed that, despite affecting drug lev...
2024-05-21 12:01
1712
Proto Axiom Launches The Challenger Summit: Australia's Premier Biotech Pitch-Event with over $250,000 in Grant Financing
SYDNEY, May 21, 2024 /PRNewswire/ -- Proto Axiom, Australia's first true biotech incubator, is thrilled to announce the launch of The Challenger Summit. The Challenger Summit will provide a unique platform for researchers to showcase their innovative biotech solutions, competing for over$250,000 ...
2024-05-21 11:28
1864
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals
SEOUL, South Korea, May 21, 2024 /PRNewswire/ -- Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the " Company") and has been supportive of the Company's mission since 2...
2024-05-21 09:49
1495
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...
2024-05-21 08:55
2321
USANA Provides Sustainable Nutrition to Malapascua Island Through Garden Tower Project
100 Garden Towers planted on the island MANILA, Philippines, May 21, 2024 /PRNewswire/ -- The USANA Foundation, the philanthropic arm of USANA Health Sciences—along with 30 USANA distributors from seven countries—recently built 100 Garden Towers on the island of Malapascua, Cebu, in pursuit of p...
2024-05-21 08:28
2101
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
* CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. * Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer...
2024-05-21 07:58
1516
Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA
* First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration * The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ transplant (SOT) or hematopoietic cell transpla...
2024-05-20 21:30
2047
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite
- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effectiveness, and efficiency in 100 papers SEOUL, South Korea, May 20, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...
2024-05-20 21:00
2013
Duoning Collaborates with Bioelectronica to Commercialize a Single-Cell Sorting System for Antibody Discovery
SHANGHAI, May 20, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess provider inChina, today announced a strategic partnership with Bioelectronica, a company focusing on developing tools for single-cell/single-bacteria research. This partnership aims to en...
2024-05-20 20:00
1791
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLog...
2024-05-20 18:00
1665
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
BORDEAUX, France, May 20, 2024 /PRNewswire/ -- TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1] Par...
2024-05-20 14:30
1690
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
YONGIN, South Korea, May 20, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval. With this approval, development of 'GC1130A' is expected to accelerate with multinational clinical trial...
2024-05-20 14:07
1465
Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year
SJMC's significant efforts in alleviating nursing shortages, enhancing workflows and its strong market-leading position, both locally and globally resulted in high patient retention and strong referrals. SAN ANTONIO, May 20, 2024 /PRNewswire/ -- Frost & Sullivan recently analyzed the hospital in...
2024-05-20 10:00
1797
Hong Kong Breast Cancer Foundation Symposium on Breast Health Education 2024
Latest Breast Cancer Diagnosis and Treatment, Integrating Traditional Chinese Medicine and Mind-Body-Spirit Healing HONG KONG, May 20, 2024 /PRNewswire/ -- Breast cancer is the most common cancer among women inHong Kong, and the third leading cause of cancer-related deaths; affecting numerous fa...
2024-05-20 08:33
1524
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-05-20 08:20
2287
Orion Health awarded Panda Health Partner status for its Orchestral Health Intelligence Platform
NEW YORK, May 19, 2024 /PRNewswire/ -- Orion Health
2024-05-19 23:10
1820
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition. TARRYTOWN, N.Y. and WASHINGTON, May 18, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: RE...
2024-05-18 05:46
3384
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400